Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases)
Autologous cell therapies are new therapeutic intervention where it introduces or uses cells or tissues from the individual, cultured, expanded and re-introduced at the site of the disease of the donor. They are widely promoted as next pillar or advancement in medical care.
Growth of the market is very rapid especially in regulatory approvals, applications areas and rapid improvements in efficacy of treatment; it has enormous advantages over allogenic stem cell therapies. Autologous transplants are relatively safe procedures, with less rates of complications and infections compared with allogenic transplants. In many instances, much of the procedure can be done on an outpatient basis. It helps in treating various dreadful diseases by transplanting their own body cells where it results in meager chances of transplant rejection.
We have also profiled leading players of this industry with their recent developments and other strategic industry activities. These include: Neostem (U.S.), Tengion (U.S.), Brainstorm Cell Therapeutics (U.S.), Dendreon Corporation (U.S.), Georgia Health Sciences University (U.S.), Regenexx (U.S.), Regeneus (Australia), Cytori Therapeutics (U.S.), Tigenix (Belgium).
Scope of the Report
This research report titled “Autologous Cell Therapy (2012-2017)” provides details about various ACT based treatments and their application areas. Every health regulatory bodies will be expecting companies and universities to develop therapy treatments, which are safer, affordable, robust, rapid, easy to use, effective and deliverable to the end user. ACT treatments for particular application areas it is safe, experiencing robust growth, minimal steps of procedure to follow and rapid in deriving the results. As for now the treatments prices are not affordable, but by the intrusion of government bodies, it will definitely experience a immense market growth.
The report gives a detailed analysis about state of the art of autologous cell therapies. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company, revenue forecasting. It includes latest therapy details and products which are available for licensing and approvals from various regulatory bodies. Using drivers, restraints and challenges it is forecasted for a period of five years i.e. 2012-2017. Opportunity strategy evaluation has been included which gives information for investors.
Autologous Cell Therapy technology is changing the medicinal treatments by introducing various new therapies. Its scope is vast and promising for the future despite challenges.
Growth of the market is very rapid especially in regulatory approvals, applications areas and rapid improvements in efficacy of treatment; it has enormous advantages over allogenic stem cell therapies. Autologous transplants are relatively safe procedures, with less rates of complications and infections compared with allogenic transplants. In many instances, much of the procedure can be done on an outpatient basis. It helps in treating various dreadful diseases by transplanting their own body cells where it results in meager chances of transplant rejection.
We have also profiled leading players of this industry with their recent developments and other strategic industry activities. These include: Neostem (U.S.), Tengion (U.S.), Brainstorm Cell Therapeutics (U.S.), Dendreon Corporation (U.S.), Georgia Health Sciences University (U.S.), Regenexx (U.S.), Regeneus (Australia), Cytori Therapeutics (U.S.), Tigenix (Belgium).
Scope of the Report
This research report titled “Autologous Cell Therapy (2012-2017)” provides details about various ACT based treatments and their application areas. Every health regulatory bodies will be expecting companies and universities to develop therapy treatments, which are safer, affordable, robust, rapid, easy to use, effective and deliverable to the end user. ACT treatments for particular application areas it is safe, experiencing robust growth, minimal steps of procedure to follow and rapid in deriving the results. As for now the treatments prices are not affordable, but by the intrusion of government bodies, it will definitely experience a immense market growth.
The report gives a detailed analysis about state of the art of autologous cell therapies. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company, revenue forecasting. It includes latest therapy details and products which are available for licensing and approvals from various regulatory bodies. Using drivers, restraints and challenges it is forecasted for a period of five years i.e. 2012-2017. Opportunity strategy evaluation has been included which gives information for investors.
Autologous Cell Therapy technology is changing the medicinal treatments by introducing various new therapies. Its scope is vast and promising for the future despite challenges.
1 INTRODUCTION
1.1 KEY TAKE AWAYS
1.2 REPORT SCOPE
1.3 RESEARCH METHODOLOGY
1.4 KEY DATA SOURCES
2 EXECUTIVE SUMMARY
3 AUTOLOGOUS CELL THERAPY (ACT)-TECHNOLOGY LANDSCAPE ANALYSIS
3.1 AUTOLOGOUS CELL THERAPY TECHNOLOGY
3.1.1 TECHNOLOGY OVERVIEW
3.1.2 TECHNOLOGY PROCESS
3.1.3 APPLICATION AREAS
3.1.3.1 NEURODEGENERATIVE DISEASES
3.1.3.2 CARDIOVASCULAR DISEASES
3.1.3.3 CANCER AND AUTOIMMUNE DISEASES
3.1.3.4 SKIN TRANSPLANTATION
3.1.3.5 INFECTIOUS DIESEASE
3.2 TECHNOLOGY TREND ANALYSIS
3.3 VALUE CHAIN ANALYSIS
4 TECHNOLOGY INVESTMENT POTENTIAL
4.1 INVESTMENT CLIMATE ASSESSMENT
4.1.1 INVESTOR NETWORKS
4.1.1.1 PUBLIC FUNDING BODIES
4.1.1.2 FUNDING/GRANTS FROM NGO ORGANIZATIONS
4.1.1.3 PRIVATE INVESTORS AND VENTURE CAPITAL FIRMS
4.1.1.4 INSIGHTS ON CURRENT AND FUTURE TECH-INVESTMENT TRENDS
4.1.1.5 INVESTOR INCLINATION AND PATTERNS
4.2 INVESTMENT OPPURTUNITIES
4.2.1 LICENSING AND ACQUISITION
4.2.2 ANALYSIS OF POTENTIAL APPLICATION AREAS FOR TECHNOLOGY INVESTMENT
5 MARKET LANDSCAPE ANALYSIS
5.1 AUTOLOGOUS Vs ALLOGENIC – MARKET LANDSCAPE
5.2 GLOBAL MARKET FORECAST
5.3 MARKET DYNAMICS
5.3.1 DRIVERS
5.3.2 RESTRAINTS
5.3.3 CHALLENGES
5.3.4 DEMAND SIDE ANALYSIS
6 ACT – TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY
6.1 INTRODUCTION
6.2 US, CANADA, LATIN AMERICA
6.3 UK, GERMANY, FRANCE
6.4 AUSTRALIA, KOREA, JAPAN, ROW
6.5 REGIONS WITH HIGH TECHNOLOGY ADOPTION
7 COMPETITIVE LANDSCAPE
7.1 MERGERS AND ACQUISITIONS
7.2 PARTNERSHIPS AND COLLABORATIONS
7.3 NEW PRODUCT DEVELOPMENT INITIATIVES (THOSE IN PIPELINE)
8 PATENT ANALYSIS
9 TECHNOLOGY ANALYSIS AND ROAD MAPPING
9.1 INTRODUCTION
9.2 CLINICAL TRIALS DETAILS – MEDICAL CENTERS AND UNIVERSITIES
9.3 DATA PERTAINING TO CELL THERAPY CLINICAL TRIALS
10 ANALYST INSIGHTS AND RECOMMENDATIONS
11 COMPANY PROFILES
11.1 ANTRIA (CRO) (U.S.)
11.2 BIOHEART (U.S.)
11.3 BRAINSTORM CELL THERAPEUTICS (U.S.)
11.4 CYTORI (U.S.)
11.5 DENDREON CORPORATION (U.S.)
11.6 FIBROCELL (U.S.)
11.7 GENESIS BIOPHARMA (U.S.)
11.8 GEORGIA HEALTH SCIENCES UNIVERSITY (U.S.)
11.9 NEOSTEM (U.S.)
11.1 OPEXA THERAPEUTICS (U.S.)
11.11 ORGENESIS (U.S.)
11.12 REGENEXX (U.S.)
11.13 REGENEUS (AUSTRALIA)
11.14 TENGION (U.S.)
11.15 TIGENIX (BELGIUM)
11.16 VIRXSYS (U.S.)
12 APPENDIX
13 GLOSSARY
1.1 KEY TAKE AWAYS
1.2 REPORT SCOPE
1.3 RESEARCH METHODOLOGY
1.4 KEY DATA SOURCES
2 EXECUTIVE SUMMARY
3 AUTOLOGOUS CELL THERAPY (ACT)-TECHNOLOGY LANDSCAPE ANALYSIS
3.1 AUTOLOGOUS CELL THERAPY TECHNOLOGY
3.1.1 TECHNOLOGY OVERVIEW
3.1.2 TECHNOLOGY PROCESS
3.1.3 APPLICATION AREAS
3.1.3.1 NEURODEGENERATIVE DISEASES
3.1.3.2 CARDIOVASCULAR DISEASES
3.1.3.3 CANCER AND AUTOIMMUNE DISEASES
3.1.3.4 SKIN TRANSPLANTATION
3.1.3.5 INFECTIOUS DIESEASE
3.2 TECHNOLOGY TREND ANALYSIS
3.3 VALUE CHAIN ANALYSIS
4 TECHNOLOGY INVESTMENT POTENTIAL
4.1 INVESTMENT CLIMATE ASSESSMENT
4.1.1 INVESTOR NETWORKS
4.1.1.1 PUBLIC FUNDING BODIES
4.1.1.2 FUNDING/GRANTS FROM NGO ORGANIZATIONS
4.1.1.3 PRIVATE INVESTORS AND VENTURE CAPITAL FIRMS
4.1.1.4 INSIGHTS ON CURRENT AND FUTURE TECH-INVESTMENT TRENDS
4.1.1.5 INVESTOR INCLINATION AND PATTERNS
4.2 INVESTMENT OPPURTUNITIES
4.2.1 LICENSING AND ACQUISITION
4.2.2 ANALYSIS OF POTENTIAL APPLICATION AREAS FOR TECHNOLOGY INVESTMENT
5 MARKET LANDSCAPE ANALYSIS
5.1 AUTOLOGOUS Vs ALLOGENIC – MARKET LANDSCAPE
5.2 GLOBAL MARKET FORECAST
5.3 MARKET DYNAMICS
5.3.1 DRIVERS
5.3.2 RESTRAINTS
5.3.3 CHALLENGES
5.3.4 DEMAND SIDE ANALYSIS
6 ACT – TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY
6.1 INTRODUCTION
6.2 US, CANADA, LATIN AMERICA
6.3 UK, GERMANY, FRANCE
6.4 AUSTRALIA, KOREA, JAPAN, ROW
6.5 REGIONS WITH HIGH TECHNOLOGY ADOPTION
7 COMPETITIVE LANDSCAPE
7.1 MERGERS AND ACQUISITIONS
7.2 PARTNERSHIPS AND COLLABORATIONS
7.3 NEW PRODUCT DEVELOPMENT INITIATIVES (THOSE IN PIPELINE)
8 PATENT ANALYSIS
9 TECHNOLOGY ANALYSIS AND ROAD MAPPING
9.1 INTRODUCTION
9.2 CLINICAL TRIALS DETAILS – MEDICAL CENTERS AND UNIVERSITIES
9.3 DATA PERTAINING TO CELL THERAPY CLINICAL TRIALS
10 ANALYST INSIGHTS AND RECOMMENDATIONS
11 COMPANY PROFILES
11.1 ANTRIA (CRO) (U.S.)
11.2 BIOHEART (U.S.)
11.3 BRAINSTORM CELL THERAPEUTICS (U.S.)
11.4 CYTORI (U.S.)
11.5 DENDREON CORPORATION (U.S.)
11.6 FIBROCELL (U.S.)
11.7 GENESIS BIOPHARMA (U.S.)
11.8 GEORGIA HEALTH SCIENCES UNIVERSITY (U.S.)
11.9 NEOSTEM (U.S.)
11.1 OPEXA THERAPEUTICS (U.S.)
11.11 ORGENESIS (U.S.)
11.12 REGENEXX (U.S.)
11.13 REGENEUS (AUSTRALIA)
11.14 TENGION (U.S.)
11.15 TIGENIX (BELGIUM)
11.16 VIRXSYS (U.S.)
12 APPENDIX
13 GLOSSARY
LIST OF TABLES
Table 1 Funding Details In Europe
Table 2 Licensing & Acquisition
Table 3 Data Pertaining To Diseases - Disease incidence & Treatment costs
Table 4 Drivers
Table 5 Restraints
Table 6 U.S. FDA Guidance Documents
Table 7 Mergers & Acquisitions
Table 8 Partnerships & Collaborations
Table 9 New Product Development Initiatives (Those In-Pipeline)
Table 10 Clinical Trials Details – Medical Centers & Universities
Table 11 Key Patents
Table 12 New Product Development Initiatives (In-Pipeline)
Table 1 Funding Details In Europe
Table 2 Licensing & Acquisition
Table 3 Data Pertaining To Diseases - Disease incidence & Treatment costs
Table 4 Drivers
Table 5 Restraints
Table 6 U.S. FDA Guidance Documents
Table 7 Mergers & Acquisitions
Table 8 Partnerships & Collaborations
Table 9 New Product Development Initiatives (Those In-Pipeline)
Table 10 Clinical Trials Details – Medical Centers & Universities
Table 11 Key Patents
Table 12 New Product Development Initiatives (In-Pipeline)
LIST OF FIGURES
FIG 1 ACT Market Revenue Forecast
FIG 2 Segmentation Of Cell Therapy
FIG 3 ACT Market Revenue Forecast
FIG 4 Percentage of shareholders in the Autologous Cell Therapy
FIG 5 Investor Networks
FIG 6 NIH Funding in USA for Autologous Cell Therapies in 2010
FIG 7 Opportunity Strategic Evaluation Analysis
FIG 8 Market Revenue of Autologous Vs Allogenic Cell Therapy Products (2011)
FIG 9 Market Share of Autologous Vs Allogenic Cell Therapy Products (2011)
FIG 10 Segmentation of Cell Therapy Treatment
FIG 11 Segmentation By Application Areas
FIG 12 Autologous Cell Therapy Market Revenue Forecast, 2012 - 2017 ($Million)
FIG 13 Market Share (%) and Revenues ($Millions) By Region (2012)
FIG 14 Market Share (%) and Revenues ($Millions) By Region (2017)
FIG 15 Market Share (%) and Revenues ($Millions) By Applications (2012)
FIG 16 Market Share (%) and Revenues ($Millions) By Applications (2017)
FIG 17 Number of M&A's in ACT technology
FIG 18 Geographical Autologous Technologies/ Product-Patent Distribution
FIG 19 Regional Data of Clinical Trials of The Technology
FIG 20 Clinical Trials By Indication
FIG 21 Stem Cell Types Employed In Interventional Clinical Trials
FIG 22 Source of Mesenchymal stem cells (MSCs)
FIG 23 Ongoing Clinical Trials
FIG 24 Number of Cell Therapy Clinical Trials By Region
FIG 25 Number of Cell Therapy Clinical Trials By Country
FIG 26 Number of PUBMED Publications
FIG 27 Country wise publication details
FIG 1 ACT Market Revenue Forecast
FIG 2 Segmentation Of Cell Therapy
FIG 3 ACT Market Revenue Forecast
FIG 4 Percentage of shareholders in the Autologous Cell Therapy
FIG 5 Investor Networks
FIG 6 NIH Funding in USA for Autologous Cell Therapies in 2010
FIG 7 Opportunity Strategic Evaluation Analysis
FIG 8 Market Revenue of Autologous Vs Allogenic Cell Therapy Products (2011)
FIG 9 Market Share of Autologous Vs Allogenic Cell Therapy Products (2011)
FIG 10 Segmentation of Cell Therapy Treatment
FIG 11 Segmentation By Application Areas
FIG 12 Autologous Cell Therapy Market Revenue Forecast, 2012 - 2017 ($Million)
FIG 13 Market Share (%) and Revenues ($Millions) By Region (2012)
FIG 14 Market Share (%) and Revenues ($Millions) By Region (2017)
FIG 15 Market Share (%) and Revenues ($Millions) By Applications (2012)
FIG 16 Market Share (%) and Revenues ($Millions) By Applications (2017)
FIG 17 Number of M&A's in ACT technology
FIG 18 Geographical Autologous Technologies/ Product-Patent Distribution
FIG 19 Regional Data of Clinical Trials of The Technology
FIG 20 Clinical Trials By Indication
FIG 21 Stem Cell Types Employed In Interventional Clinical Trials
FIG 22 Source of Mesenchymal stem cells (MSCs)
FIG 23 Ongoing Clinical Trials
FIG 24 Number of Cell Therapy Clinical Trials By Region
FIG 25 Number of Cell Therapy Clinical Trials By Country
FIG 26 Number of PUBMED Publications
FIG 27 Country wise publication details
